ayuVeer®

Veerhealth Care Ltd.

CIN : L65910MH1992PLC067632

Date: 14.08.2026

To,
BSE Limited
Department of Corporate Services
P. J. Towers, Dalal Street,
Mumbai - 400001
Scrip Code: 511523

Subject: Press Release on Q1FY27 Standalone Un-Audited Financial Highlights

Dear Sir/Ma'am,

We are enclosing herewith the press release on highlights of Q1FY27 Standalone Un-Audited Financial Reports along with orders announced till now.

You are requested to take the same on record.

Thanking you.

Yours faithfully

For Veerhealth Care limited

BHAVIN
SATISH
SHAH

Digitally signed by BHAVIN SATISH SHAH
DN: c=IN, st=Maharashtra,
2.5.4.20=52ce4b69d7fdb3a90c91ddfee5a2fff6e38beb802aa3922b5f6d411414c3a576,
postalCode=400092, street=Near Pawar Public School Mumbai Borivali West,
pseudonym=3b96acd5-e0aa-4ffc-a665-17beba26d314, title=9128,
serialNumber=ca6ec2cdac33664b7d5756748187e953db3886ae682190f75754ab671040ac96,
o=Personal, cn=BHAVIN SATISH SHAH
Date: 2026.08.14 02:12:28 +05'30'

VEERHEALTH CARE LTD.
MUMBAI

Bhavin S. Shah
Managing Director
DIN: 03129574

VeerHealth Care Ltd.
NATURE-AL DIRECTION TO REMEDIES

Veerhealth Care Limited Reports Historical Q1FY27 Results reporting 388.13% YoY growth at ₹ 25.09 Crore in Total Revenues, 233.87% YoY growth at ₹ 2.07 Crore in EBITDA & 412.50% YoY growth at ₹ 1.23 Crore in PAT

Mumbai – 14th August, 2026: Veerhealth Care Limited (BSE: VEERHEALTH), Veerhealth Care is India's one of the fastest growing and only Vegan Ayurvedic & Herbal Cosmetic Listed company. Ayuveer, backed by Veerhealth Care's expertise in Ayurveda, specializes in crafting ayurvedic medicines and oral care products with natural ingredients. With a focus on quality and affordability, Ayuveer aims to offer an exceptional and safe daily care experience to its customers.

Q1FY27 Standalone Un-Audited Financial Highlights

- Total Revenues of ₹ 25.09 Crore, YoY **growth of 388.13%**
- EBITDA of ₹ 2.07 Crore, YoY **growth of 233.87%**
- EBITDA Margin of 8.25% YoY **decline of 381 BPS**
- Net Profit of ₹ 1.23 Crore, YoY **growth of 412.50%**
- Net Profit Margin of 4.90%, YoY **growth of 23 BPS**

Orders Announced till now in FY27:

1. Orders from New York -based Company for supply of body care products for a value aggregating to ₹293 Lakhs
2. Orders from one of India's Fast Moving Consumer Goods (FMCG) company for skincare products aggregating to ₹ 1824.40 Lakhs
3. Order from India's Leading large Retail network of pharmacies and healthcare company aggregating to ₹111 Lakhs
4. Recently company got a Sample Order worth around ₹15.74 Lakhs for supply of Gripe Water from an established buyer based out of Sudan. This export order marks the Company's first strategic entry into the Sudan market, expanding global presence in the pediatric and wellness care segment. The Company anticipates leveraging this Sample order to build long-term relationships and further capitalize on growing opportunities across the African region.

Key Highlights:

- Veerhealth Care has received USFDA clearance, enabling exports of Drug (OTC) products to the USA and unlocking access to other international markets, in line with its "Local to Global" vision. It is one of the leading small-cap companies in India in the Food & Drug (OTC) segment with a USFDA-approved plant. Despite its size, the Company is now in the league of larger players, eligible for larger export orders. Globally, very few small-cap companies have secured USFDA plant clearance, positioning Veerhealth Care in a distinctive category.

VEERHEALTH CARE LTD. MUMBAI

- Discussions with a major Russian group for oral care exports has entered advanced stage; Veerhealth Care expects entry into Russian market very soon.
- Completed onboarding of Ayuveer products on Myntra, expanding e-commerce presence. Now present across Amazon, Flipkart, Nykaa, Glowroad, Jiomart, and Myntra.
- Commenced production at new facility with in-house plastic molding for packaging and backward integration.

In Current F.Y. 2026-27 we are expecting Total Income of ₹ 105 crores with PAT of minimum ₹ 5 - 6 crores.

In F.Y. 2027-28 we are expecting Total Income of ₹ 156 crores with PAT of minimum ₹ 9 - 10 crores

The India-EU Trade Deal 2026 is transforming the future of Modern Ayurveda exports from India, opening new growth opportunities in the global wellness market.

Currently we are in advanced stages of talk with one of India's largest hotel amenities supplier having Indo-Canadian joint venture.

Globally, very few small-cap companies have secured USFDA plant clearance, positioning Veerhealth Care in a distinctive category.

Commenting on the financial performance, Mr. Bhavin Shah - Managing Director of Veerhealth Care Limited, said, "I am delighted with the progress we have made in Q1FY27 by reporting **Highest ever Quarterly Total Income of ₹25.09 crore,** driven by our consistent focus on expanding our international footprint and strengthening our domestic presence. The growth in our Export Sales and the addition of new product categories have significantly bolstered our position in the global and local markets. **Going ahead we expect to maintain the high growth rates which we have delivered till now in this Financial Year.**

Our ability to secure multiple high-value export orders, including those from top institutional suppliers, underscores the trust in our product quality and commitment to excellence. The expansion of our manufacturing footprint further reflects our proactive approach to meeting growing demand and enhancing our production capabilities. These achievements are a testament to our strategy and pave the way for sustained growth and value creation in the coming quarters."

In line with its "Local to Global" ambition, Veerhealth Care is actively working towards scaling its manufacturing and export operations for products under the medical device category in the U.S. market.

Veerhealth Care Ltd. specializes in manufacturing of Pure Vegetarian Toothpaste

Disclaimer

VEERHEALTH CARE LTD.
MUMBAI